Mode
Text Size
Log in / Sign up

Phacoemulsification addition to ab-interno canaloplasty does not significantly improve intraocular pressure or medication reductionAdding cataract surgery to canaloplasty does not change glaucoma results

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that adding phacoemulsification to ab-interno canaloplasty does not significantly improve IOP or medication reduction.

This meta-analysis evaluated the efficacy of ab-interno canaloplasty (ABiC) with phacoemulsification (ABiC+Phaco) compared to standalone ABiC for patients with open-angle glaucoma. The analysis pooled data from 663 eyes to assess intraocular pressure (IOP) and medication reduction over a 3-year follow-up period.

The primary finding indicates no significant difference in IOP-lowering efficacy between the ABiC+Phaco group and the standalone ABiC group at 6 months, 1 year, 2 years, and 3 years (95% CI: -0.98 to 1.48). Similarly, there was no significant difference in glaucoma medication reduction between the two groups across all timepoints (95% CI: -0.18 to 0.23). A small IOP-lowering benefit of 0.75 mmHg (95% CI: 0.03 to 1.47) was noted specifically in primary OAG-only studies.

The authors note a moderate risk of bias across all included studies, which may impact the certainty of these findings. Clinically, the data suggest that adding phacoemulsification to ab-interno canaloplasty may not provide significant additional benefits regarding IOP reduction or medication reduction for patients with open-angle glaucoma.

How this fits prior evidence

This meta-analysis addresses a gap in understanding whether combining surgical techniques improves outcomes in open-angle glaucoma. While previous evidence has identified biomarkers like C-reactive protein and predictors of progression such as baseline disc hemorrhage, this study specifically evaluates the comparative efficacy of ABiC with or without phacoemulsification. The findings suggest that phacoemulsification does not offer significant additional IOP reduction compared to standalone ABiC.

Living with open-angle glaucoma means managing eye pressure to protect your vision. Doctors sometimes combine two procedures: ab-interno canaloplasty (ABiC) and phacoemulsification, which is a common way to treat cataracts. Some people wonder if adding the cataract treatment provides extra protection against glaucoma.

A review of data from 663 eyes shows that combining these two procedures does not offer more benefits than doing the canaloplasty alone. At every checkup point up to three years, both methods lowered eye pressure and reduced the need for medication in the same way. While one specific group of studies showed a tiny difference in favor of the combined approach, it was not large enough to be considered significant.

Because there is a moderate risk of bias in the data used for this review, these results should be viewed with some caution. For now, adding cataract surgery to the canaloplasty procedure does not appear to provide extra benefits for managing glaucoma pressure or reducing medication use.

What this means for you:
Combining cataract surgery with canaloplasty does not offer additional benefits for lowering eye pressure in glaucoma.

Common questions

Does adding cataract surgery help lower eye pressure?

No, the study found no significant difference in how well the combined procedure worked compared to doing the canaloplasty alone. At 6 months, 1 year, 2 years, and 3 years, both methods were equally effective at lowering intraocular pressure.

Will combining these procedures reduce my need for eye drops?

The data shows no significant difference in reducing glaucoma medication between the combined procedure and the standalone canaloplasty. Both options resulted in similar levels of medication reduction across all timepoints studied over the three-year period.

Is one treatment better for people with only open-angle glaucoma?

In studies focusing only on patients with open-angle glaucoma, there was a very small benefit in pressure reduction for the combined procedure. However, this difference was not large enough to be considered significant compared to the standalone procedure.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Ab-interno canaloplasty (ABiC) may be performed as a standalone procedure or in combination with phacoemulsification (ABiC+Phaco). This study aims to examine the comparative surgical outcomes of both procedures. METHODS: PubMed, EMBASE and CENTRAL were searched for randomised controlled trials, cohort studies and retrospective case series published from inception to 31 March 2025 that compared outcomes of standalone ABiC and ABiC+Phaco in the treatment of open-angle glaucoma (OAG). Random-effects meta-analysis was performed to pool the mean difference in intraocular pressure (IOP) and glaucoma medications compared to baseline. RESULTS: Eight studies with a pooled total of 663 eyes were included in final analysis. There was no significant difference in IOP-lowering efficacy between ABiC+Phaco and standalone ABiC across all timepoints (6 months, 1 year, 2 years and 3 years) with a mean difference of 0.25 mmHg (95% CI: -0.98 to 1.48) at 3 years. There was also no significant difference in glaucoma medication reduction between ABiC+Phaco and standalone ABiC across all timepoints, with a mean difference of 0.03 medication reduction (95% CI: -0.18 to 0.23) at 3 years. A small IOP-lowering benefit of ABiC+Phaco versus standalone ABiC in primary OAG-only studies (mean difference 0.75 mmHg, 95% CI: 0.03-1.47) was observed at 3 years. CONCLUSION: Our meta-analysis suggests that phacoemulsification may not offer significant additional IOP and glaucoma medication reduction to standalone ABiC. However, results should be interpreted with caution due to a moderate risk of bias across all included studies. Regardless, our findings are consistent with existing literature on the effect of adjunctive phacoemulsification on other ab-interno MIGS.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.